免费看av的,欧美一性一乱一交一视频多男,日韩影院一区,羞羞视频一区二区,国产专区中文字幕,精品免费av,男女av免费观看

EN
×
EN
  • 業(yè)務(wù)咨詢

    中國:

    Email: marketing@medicilon.com.cn

    業(yè)務(wù)咨詢專線:400-780-8018

    (僅限服務(wù)咨詢,其他事宜請撥打川沙總部電話)

    川沙總部電話: +86 (21) 5859-1500

    海外:

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在線留言×
點(diǎn)擊切換
Customer Center
客戶中心
May 28,2025
美迪西祝賀合作伙伴領(lǐng)諾醫(yī)藥新一代補(bǔ)體抑制劑啟動(dòng)一期臨床研究
?美迪西作為領(lǐng)諾醫(yī)藥的合作伙伴,為SLN12140提供了體外藥效、藥代、安評等一站式臨床前研發(fā)服務(wù),為該藥物盡早進(jìn)入臨床階段奠定了堅(jiān)實(shí)基礎(chǔ)。
查看更多
美迪西祝賀合作伙伴領(lǐng)諾醫(yī)藥新一代補(bǔ)體抑制劑啟動(dòng)一期臨床研究
May 21,2025
國內(nèi)首款長效鎮(zhèn)痛新藥!美迪西祝賀清普生物美洛昔康注射液(Ⅱ)中美兩地獲批上市
上海美迪西生物醫(yī)藥股份有限公司作為清普生物合作伙伴,為美洛昔康注射液(Ⅱ)提供了部分關(guān)鍵臨床前研發(fā)服務(wù),為其快速獲批上市奠定基礎(chǔ)。
查看更多
國內(nèi)首款長效鎮(zhèn)痛新藥!美迪西祝賀清普生物美洛昔康注射液(Ⅱ)中美兩地獲批上市
May 21,2025
美迪西助力復(fù)星醫(yī)藥LBP-ShC4治療雄激素脫發(fā)(AGA)I期臨床試驗(yàn)獲FDA批準(zhǔn)
美迪西作為菌濟(jì)健康合作伙伴,為LBP-ShC4提供了體內(nèi)藥效、藥代、安評等臨床前研發(fā)服務(wù),助力該項(xiàng)目突破傳統(tǒng)研發(fā)瓶頸,降低研發(fā)成本,加速臨床轉(zhuǎn)化進(jìn)程。
查看更多
美迪西助力復(fù)星醫(yī)藥LBP-ShC4治療雄激素脫發(fā)(AGA)I期臨床試驗(yàn)獲FDA批準(zhǔn)
May 14,2025
美迪西祝賀祐森健恒IL-17A抑制劑UA026完成首例受試者給藥
上海美迪西生物醫(yī)藥股份有限公司作為祐森健恒的合作伙伴,為UA026的臨床前研發(fā)提供了藥代動(dòng)力學(xué)、安全性評價(jià)服務(wù),以專業(yè)高效的技術(shù),為該藥快速獲批臨床奠定了堅(jiān)實(shí)基礎(chǔ)。
查看更多
美迪西祝賀祐森健恒IL-17A抑制劑UA026完成首例受試者給藥
Jun 12,2025
雙靶向HDAC抑制劑和ATM激活劑SP-1-303抑制雌激素受體陽性乳腺癌細(xì)胞生長,本研究中PK實(shí)驗(yàn)通過美迪西進(jìn)行
Dual-targeting chromatin regulation and DNA damage repair signaling presents a promising avenue for cancer therapy. SP-1-303 acts as a class I isoform selective histone deacetylase (HDAC) inhibitor and an activator of the ataxia-telangiectasia mutated protein (ATM). SP-1-303 emerges as a novel second generation class I (HDAC1 and HDAC3) selective HDAC inhibitor, and ATM activator, capable of modulating estrogen receptor (ER) expression, and inhibiting growth of ER+ BC cells. Combined targeting of class I HDACs and ATM by SP-1-303 offers a promising therapeutic approach for treating ER+ breast cancers and supports further preclinical evaluation.
查看更多
雙靶向HDAC抑制劑和ATM激活劑SP-1-303抑制雌激素受體陽性乳腺癌細(xì)胞生長,本研究中PK實(shí)驗(yàn)通過美迪西進(jìn)行
Jun 12,2025
抗逆轉(zhuǎn)錄病毒療法(ART)預(yù)防圍產(chǎn)期HIV感染,本研究中多替拉韋鈉鹽和游離態(tài)均由美迪西提供
Vertical transmission accounts for most human immunodeficiency virus (HIV) infection in children, and treatments for newborns are needed to abrogate infection or limit disease progression. A hallmark of human immunodeficiency virus type 1 (HIV-1) infection is the early establishment of a persistent viral reservoir1. Daily antiretroviral therapy (ART), the current standard of care, can reduce plasma viral load (PVL) to undetectable levels, but treatment interruption results in viral rebound. Being small molecules, ART drugs rapidly diffuse to distal sites; for instance, DTG was detectable at therapeutically relevant concentrations in colorectal tissue within 1?h of a single oral dose in a Phase I trial.
查看更多
抗逆轉(zhuǎn)錄病毒療法(ART)預(yù)防圍產(chǎn)期HIV感染,本研究中多替拉韋鈉鹽和游離態(tài)均由美迪西提供
Jun 12,2025
通過增強(qiáng)MTUS1穩(wěn)定性抑制透明細(xì)胞腎細(xì)胞癌轉(zhuǎn)移,本研究中體外實(shí)驗(yàn)重組蛋白通過美迪西合成和純化
Clear cell renal cell carcinoma (ccRCC) is the most prevalent histological subtype of kidney cancer and is believed to mainly originate from proximal tubular epithelial cells of the nephron. MTUS1 was significantly downregulated in ccRCC tissues, especially in metastatic tissues. Knockdown of MTUS1 decreased microtubule stability, whereas increased microtubule dynamics by promoting the ratio of unphosphorylated KIF2CS192 adapting to high motility of metastatic cancer cells. MTUS1 is a potent microtubule-stabilizing protein19, so we assessed the impact of MTUS1 knockdown on microtubule dynamics. MTUS1 regulates microtubule dynamics via promoting KIF2CS192 phosphorylation by Aurora B. Western blot and immunohistochemistry further confirmed significantly lower expression of SORBS2 protein in metastatic tissues than that in primary tissues and normal tissues.
查看更多
通過增強(qiáng)MTUS1穩(wěn)定性抑制透明細(xì)胞腎細(xì)胞癌轉(zhuǎn)移,本研究中體外實(shí)驗(yàn)重組蛋白通過美迪西合成和純化
Jun 12,2025
新型5-HT3受體配體有望用于治療神經(jīng)精神疾病和胃腸道疾病,本研究中藥理藥效學(xué)研究通過美迪西進(jìn)行
Droxytryptamine (5-HT; serotonin) 5-HT3 receptor is an excitatory ligandgated ion channel expressed in for example the brain and the gastrointestinal tract. CSTI-300 as a selective, high affinity 5-HT3 receptor partial agonist. CSTI-300 was examined alongside the selective 5-HT3 receptor antagonist alosetron (which is also currently marketed as a therapeutic for IBS-d). Sub-cutaneous application of 5-hydroxytryptophan (5-HTP; 10 mg/kg) markedly increased the rat’s sensitivity to abdominal contractions. CSTI-300 and Alosetron displayed similar efficacy in a rodent in vivo model of IBS-d, measured by a reduction in colonic sensitivity. The experiments (Rat colon distension model of IBS-d) were carried out by Medicilon. The protocol complied with and was approved by the Institutional Animal Care and Use Committee and Medicilon is accredited by the NIH Office of laboratory Animal Welfare (OLAW) and AAALAC. Experiments (dog behavioural and emesis model) were performed by Medicilon. The protocol for the dog behavioural and emesis model complied with and was approved by the Institutional Animal Care and Use Committee.
查看更多
新型5-HT3受體配體有望用于治療神經(jīng)精神疾病和胃腸道疾病,本研究中藥理藥效學(xué)研究通過美迪西進(jìn)行
Jun 11,2025
丁烯酸內(nèi)酯是一種很有前景的天然防污產(chǎn)品,本研究中純度>99%的丁烯酸內(nèi)酯通過美迪西合成
Butenolide is a promising antifouling natural product. Rosin-based antifouling paint with the incorporation of butenolide, a promising antifoulant, possesses the potential to deter the settlement of marine organisms on submerged surfaces. Butenolide with a purity >99% was synthesized by Medicilon, Inc. (Shanghai, China).
查看更多
丁烯酸內(nèi)酯是一種很有前景的天然防污產(chǎn)品,本研究中純度>99%的丁烯酸內(nèi)酯通過美迪西合成
Jun 11,2025
第二代前列腺素受體拮抗劑,本研究中眼部PK實(shí)驗(yàn)通過美迪西進(jìn)行
?Prostanoids are established mediators of inflammation, and the therapeutic efficacy of drugs that block their global biosynthesis in conditions such as rheumatoid arthritis is well-known. AGN 225660 blocks pro-inflammatory prostanoid receptors (DP1, EP1, EP4, FP, TP). AGN 225660 represents a second-generation compound with an “druggable” core structure. AGN 225660 exhibited good ocular bioavailability and was active in reducing ocular inflammation associated with phacoemulsification surgery, lipopolysaccharide (LPS), and arachidonic acid induced uveitis. Ocular Pharmacokinetic studies were performed at Medicilon.
查看更多
第二代前列腺素受體拮抗劑,本研究中眼部PK實(shí)驗(yàn)通過美迪西進(jìn)行
×
搜索驗(yàn)證
點(diǎn)擊切換